Preemption In Cosmetics Bill Would Offset Burden, But To What Degree?
This article was originally published in The Rose Sheet
Executive Summary
States would be barred from establishing cosmetic ingredient restrictions that conflict with final FDA review determinations, as well as requirements related to cosmetics registration, good manufacturing practices or adverse-event reporting, under a preemption clause in the Personal Care Products Safety Act, introduced April 20. The bill would help address the growing problem of inconsistent regulations from one state to the next, but exceptions and potential gray areas raise questions about how effective the provision would be.